Autopsy report · NCT02153632
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 135 participants enrolled.
- Results were posted on the registry 2 years 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Adamas Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Parkinson's Disease; Levodopa Induced Dyskinesia (LID)
- Interventions
- amantadine HCl ER; Placebo
- Participants
- 135
- Sites
- 56
- Countries
- Canada, France, Germany, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.